Yorgancıoğlu, Arzu
Aksu, Kurtuluş
Naycı, Sibel Atış
Ediger, Dane
Mungan, Dilşad
Gül, Umut
Beekman, Maarten J. H. I.
Kızılırmak, Deniz
Altıntaş, Nejat
Bulut, İsmet
Çağatay, Tülin
Gemicioğlu, Bilun
İnce, Özgür
Oğuzülgen, Kıvılcım
Kalpaklıoğlu, Füsun
Baççıoğlu, Ayşe
Aksu, Funda
Altuntaş, Murat
Erkekol, Ferda Öner
Karakaya, Gül
Kalyoncu, Ali Fuat
Damadoğlu, Ebru
Hanta, İsmail
Altunok, Ersoy
Özer, Adviye
Yuluğ, Demet Polat
Gülbaş, Gazi
Süerdem, Mecit
Yormaz, Burcu
Ceylan, Emel
Erge, Duygu
Çilli, Aykut
Doğan, Berat Celil
Erel, Fuat
Sevinç, Can
Anar, Ceyda
Pekbak, Gülseren
Erbay, Müge
,
Article History
Received: 17 November 2021
Accepted: 28 April 2022
First Online: 2 June 2022
Declarations
:
: The study was conducted in compliance with the study protocol, local ethics committees and the Declaration of Helsinki. The study protocol was approved by Celal Bayar University Ethics Committee and Turkish Ministry of Health ethics committee. Signed informed consent was collected from participating patients or legal guardians of patients aged < 18 years.
: Not applicable.
: AY has received research grants from MSD, AstraZeneca and Sanofi as a principal investigator/collaborator, received honoraria from AstraZeneca, Abdi İbrahim, GSK, Novartis Sandoz, Sanofi, and Chiesi and served as a consultant/advisory member for AstraZeneca, GSK, Novartis, Sanofi, Chiesi, and Deva. KA has received research support from Sanofi, AstraZeneca, Health Institutes of Turkey (TUSEB) and received consulting or scientific speaking fees from AstraZeneca, GlaxoSmithKline, Novartis, Sandoz, Chiesi, İbrahim Etem, Abdi İbrahim, Deva and Acino. SAN has received research grants from AstraZeneca, Bayer, GSK, Novartis, Sanofi as a principal investigator, received honoraria from AstraZeneca, Chiesi, GSK and Novartis Sandoz and served as consultant advisory board member Astra-Zeneca, Chiesi, Deva, GSK and Novartis Sandoz. DE served as speaker for Novartis, GSK, AstraZeneca, Vem ilaç and as a clinical research investigator for MSD, AstraZeneca, Sanofi, GSK. DE is also ad-board member at Novartis and GSK. DM received grants from AstraZeneca and Sanofi as a principal investigator, received honoraria from Abdi İbrahim, GSK, Novartis and served as a consultant/advisory member for ALK, Chiezi, GSK and Novartis. UG is an employee of AstraZeneca. MJHIB was an employee of AstraZeneca when this study was conducted and has shares in AstraZeneca.